rivastigmine hydrogen tartrate
PolandMedications containing this active substance
-
Ristidic
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 2.4 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
Ristidic
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 4.8 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
Ristidic
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 7.2 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
Ristidic
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 9.6 mg ATC: N06DA03
Manufacturer: Bausch Health Poland Sp. z o.o.
-
Rivastigmine neuropharma
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 2.4 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
Rivastigmine neuropharma
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 4.8 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
Rivastigmine neuropharma
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 7.2 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
Rivastigmine neuropharma
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 9.6 mg ATC: N06DA03
Manufacturer: Genepharm S.A. neuraxpharm Arzneimittel GmbH
-
Rivastigmine orion
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 2.4 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma
-
Rivastigmine orion
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 4.8 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma
-
Rivastigmine orion
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 7.2 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma
-
Rivastigmine orion
Form: capsules, hard
Active substance Dosage rivastigmine hydrogen tartrate 9.6 mg ATC: N06DA03
Manufacturer: Orion Corporation Orion Pharma